An Open-label Phase 2 Multi-center Study of Enzalutamide and Abiraterone and Biomarkers of Androgen Response and Resistance During Rising PSA: BARRIER-P Trial
Phase of Trial: Phase II
Latest Information Update: 15 Apr 2016
At a glance
- Drugs Abiraterone acetate (Primary) ; Enzalutamide (Primary) ; Prednisone
- Indications Prostate cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms BARRIER-P
- 11 Apr 2016 Status changed from not yet recruiting to recruiting.
- 21 Dec 2015 Planned initiation date changed from 1 Jun 2015 to 1 Jan 2016, according to ClinicalTrials.gov record.
- 06 May 2015 New trial record